Sanofi (SNY) said Wednesday its investigational efdoralprin alfa fusion protein has received the European Medicines Agency's orphan drug designation to potentially treat alpha-1 antitrypsin deficiency-related emphysema, a rare respiratory condition.
The decision was based on efdoralprin alfa meeting all primary and secondary endpoints in a global phase 2 trial.
Efdoralprin alfa has already received the US Food and Drug Administration's fast track and orphan drug designations, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments